Project Grant R21EY036677
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$251K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award of $422,199 from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to explore a new therapeutic approach for treating meibomian gland dysfunction (MGD), a leading cause of dry eye disease. The research aims to investigate the use of estrogen receptor (ER) inhibitors, such as tamoxifen and fulvestrant, to suppress ER activity and increase androgen receptor (AR) function in the meibomian glands, with the goal of enhancing...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $442,750 to the University of California, Davis to define a new model of evaporative dry eye disease (EDED). The research aims to: Define the clinical, topographical, and ultrastructural abnormalities of the ocular surface in AWAT2 knockout mice, which exhibit a dysfunctional tear film lipid layer similar to human EDED. Determine the impact of EDED on the corneal epithelial barrier...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports research to investigate the role of Müller glia in the retinal inflammatory response to stress, injury, and disease. The $606,034 award to St. Jude Children's Research Hospital Inc. will fund a 5-year study to profile the acute and chronic inflammatory pathways in the retina across various disease models, with a focus on the coordinating function of Müller glia. The research aims to...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to investigate the relationship between myofibroblasts and alloreactive T cells in corneal transplantation. The $540,213 award to The Schepens Eye Research Institute, Inc., effective August 1, 2025 through July 31, 2030, aims to: 1) define the mechanisms by which myofibroblasts regulate alloreactive effector T cell function, and 2) define the mechanisms by...
This $670,496 Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to investigate the paradoxical role of anti-VEGF therapy in subretinal fibrosis (SRF) associated with neovascular age-related macular degeneration (NAMD). The project aims to elucidate the mechanisms by which anti-VEGF therapy at different disease stages impacts SRF, and to develop novel dual anti-angiogenesis and anti-fibrosis therapies. The...
The National Eye Institute (NEI) awarded a $568,122 Project Grant under the Vision Research program (CFDA 93.867) to Baylor College of Medicine to conduct research on the role of vascular ligands and neurovascular dysfunction in glaucoma. The project aims to systematically identify endothelial cell-specific ligands that can modulate retinal ganglion cell function and survival in glaucoma, with the goal of developing novel neuroprotective therapies. The award period runs from July 1, 2025 to...
This Project Grant award for $383,000 from the National Eye Institute (CFDA 93.867 - Vision Research) aims to identify social determinants of health (SDOH) indicators associated with disparities in the diagnosis, management, and prognosis of dry eye disease. The project will leverage electronic health record data from a single-center and multi-center (Sight Outcomes Research Collaborative) datasets to build prognostic models that account for individual and structural barriers to accessing eye...